During the last session, Abeona Therapeutics Inc. (NASDAQ:ABEO)’s traded shares were 1,344,622, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $1.62, reflecting an intraday loss of -4.71% or -$0.08. The 52-week high for the ABEO share is $3.79, that puts it down -133.95% from that peak though still a striking +38.89% gain since the share price plummeted to a 52-week low of $0.99. The company’s market capitalization is $160.04 Million, and the average intraday trading volume over the past 10 days was 1.51 Million shares, and the average trade volume was 4.24 Million shares over the past three months.
Abeona Therapeutics Inc. (ABEO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.7. ABEO has a Sell rating from none of the analyst(s) out of 3 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 3 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.18.
Abeona Therapeutics Inc. (NASDAQ:ABEO): Trading Information
Abeona Therapeutics Inc. (ABEO) registered a -4.71% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 19% in intraday trading to $2.00E this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is -11.96%, and it has moved by -19.4% in 30 days. Despite these dips, the overall price performance for the year is 3.18%. The short interest in Abeona Therapeutics Inc. (NASDAQ:ABEO) is 5.78 Million shares and it means that shorts have 1.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.67, which implies an increase of 250% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $8 respectively. As a result, ABEO is trading at a discount of 393.83% off the target high and 146.91% off the low.
Abeona Therapeutics Inc. (ABEO) projections and forecasts
Statistics show that Abeona Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Abeona Therapeutics Inc. (ABEO) shares have gone up +48.62% during the last six months, with a year-to-date growth rate more than the industry average at 32.73% against 8.4%. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 65.4% this quarter and then fall -35.7% in the quarter after that. In the rating firms’ projections, revenue will decline -95% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -11.5%. While earnings are projected to return 40% in 2021, the next five years will return 0% per annum.
Abeona Therapeutics Inc. (NASDAQ:ABEO)’s Biggest Investors
Abeona Therapeutics Inc. insiders own 14.94% of total outstanding shares while institutional holders control 34.44%, with the float percentage being 40.49%. Adage Capital Partners GP L.L.C. is the largest shareholder of the company, while 114 institutions own stock in it. As of Dec 30, 2020, the company held over 8.29 Million shares (or 8.39% of all shares), a total value of $13.01 Million in shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The next largest institutional holding, with 4.09 Million shares, is of Blackrock Inc.’s that is approximately 4.14% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $6.42 Million.
Also, the Mutual Funds coming in first place with the largest holdings of Abeona Therapeutics Inc. (ABEO) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 1,931,895 shares. This amounts to just over 1.96 percent of the company’s overall shares, with a $3.03 Million market value. The same data shows that the other fund manager holds slightly less at 1.48 Million, or about 1.5% of the stock, which is worth about $3.58 Million.